StockData
Teva Pharmaceutical Industries Ltd logo

Teva Pharmaceutical Industries Ltd

TEVANYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30128% above fair value
$42.62+0.05 (+0.12%)

Close on Nov 17, 2026Market cap $49.66BP/E 71.0Yield –

Teva Pharmaceutical Industries Proceeds from Sale of Businesses and Long-Lived Assets by Quarter

Proceeds from Sale of Businesses and Long-Lived Assets ($M)

Teva Pharmaceutical Industries Proceeds from Sale of Businesses and Long-Lived Assets: $47M in Q3 2026, up 487.5% from a year earlier.

Latest, Q3 2026
47
Period ended Sep 30, 2026
Change on a year earlier
+487.5%
8 in Q3 2025
History
35 quarters
Since Q1 2018
Sources
26
Documents cited below

Where the Q3 2026 figure comes from

“|| Proceeds from sale of businesses and long-lived assets, net | 47 | 8”

Source: SEC Form 10-Q (0000818686-26-000006) ↗

Reported in SEC Form 10-K / Form 10-Q / Form 8-K Earnings Releases.

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedProceeds from Sale of Businesses and Long-Lived Assets ($M)Year on yearSource
Q3 2026Sep 30, 202647+487.5%SEC Form 10-Q (0000818686-26-000006) ↗
Q2 2026Jun 30, 20264-55.6%SEC Form 10-Q (0001193125-26-323619) ↗
Q1 2026Mar 31, 202642+147.1%SEC Form 10-Q (0001193125-26-191513) ↗
Q4 2025Dec 31, 20250-100.0%SEC Form 10-K (0001193125-26-034532) ↗
Q3 2025Sep 30, 20258-78.9%SEC Form 10-Q (0000818686-26-000006) ↗
Q2 2025Jun 30, 20259+800.0%SEC Form 10-Q (0001193125-26-323619) ↗
Q1 2025Mar 31, 202517–SEC Form 10-Q (0001193125-26-191513) ↗
Q4 2024Dec 31, 20244–SEC Form 10-K (0001193125-26-034532) ↗
Q3 2024Sep 30, 202438+280.0%SEC Form 10-Q (0001193125-25-266895) ↗
Q2 2024Jun 30, 20241-98.2%SEC Form 10-Q (0001193125-25-169296) ↗
Q1 2024Mar 31, 20240-100.0%SEC Form 10-Q (0001193125-25-114889) ↗
Q4 2023Dec 31, 20230-100.0%SEC Form 10-K (0001193125-26-034532) ↗
Q3 2023Sep 30, 202310+400.0%SEC Form 10-Q (0001193125-24-252039) ↗
Q2 2023Jun 30, 202356+211.1%SEC Form 10-Q (0001193125-24-189924) ↗
Q1 2023Mar 31, 20232-92.0%SEC Form 10-Q (0001193125-24-134200) ↗
Q4 2022Dec 31, 202223-45.2%SEC Form 10-K (0001193125-25-020826) ↗

Cite this data

StockData. (2026). Teva Pharmaceutical Industries Proceeds from Sale of Businesses and Long-Lived Assets ($M), quarterly Q1 2018–Q3 2026 [Data set]. Compiled from Teva Pharmaceutical Industries SEC filings and investor materials. https://stockdatahq.com/stocks/teva/kpis/fcf-divest-proceeds

See every metric in the Teva Pharmaceutical Industries KPI table. Data updated Nov 10, 2026.

See a number that looks wrong?